# A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

> **NCT00002359** · PHASE3 · COMPLETED · sponsor: **The Immune Response Corporation** · enrollment: 3000 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** HIV-1 Immunogen

## Key facts

- **NCT ID:** NCT00002359
- **Lead sponsor:** The Immune Response Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 3000 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002359, "A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00002359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*